- Point of View: Overcoming barriers to affordability of orally inhaled products while protecting innovation
- Nasal and trans-nasal lung deposition of aerosols
- A clinically relevant approach to assess in vitro bioequivalence for regulatory approval of DPIs: A case study
- Accelerating inhalation product development: Choosing between outsourcing and developing internal capabilities
- Technology selection in capsule-based inhalation product development
- Dry powder inhalers—More than 170 years of development; Where to next?
- Testing and comparison of puncturing forces for gelatin and HPMC inhalation capsules
- Spray pattern as a screening tool during early development of nasal sprays
- Spray-granulated mannitol as a viable alternative to lactose in DPI formulations: Preparation of ordered mixtures and storage stability
- Connected inhalers: Stakeholders’ potential benefits and possible concerns
- Nebulizers: Past to present platforms and future possibilities (2018)
- Back Page: Reducing carbon footprints of metered dose inhalers
- Back Page: Comic books help educate kids about asthma and proper inhaler use
- Back Page: Inhalatorium: A website dedicated to the history of inhalation therapy
- Back Page: Increasing participation in and improving outcomes from pMDI training
- Regulatory considerations for cybersecurity and data privacy in digital health and medical applications and products
- Evaluating simulated patient use in realistic nasal airway models for the in vitro characterization of nasal spray products
- The importance of human factors in inhaler development: The making of PowdAir®
- The evolution of DPI capsules
- The effect of shaking on solution MDIs
- Selecting an MDI can
- Selecting a nasal spray pump
- Selecting a dose counter
- Quality by design: Considerations for inhalation product development
- Principles of nebulizer technology
- Overlooked opportunities for nebulizers in inhalation product development
- Nebulizers: Past to present platforms and future possibilities (2016)
- Nasal spray regulatory approval
- Nasal drug delivery devices: Past, present and future device innovations for the would-be product developer
- Nasal and sublingual spray delivery devices: Market opportunities and unmet medical needs
- Intranasal Vaccines: Protecting Public Safety
- Inhaled drug product development: A unique form of product life cycle management
- Improving dose reproducibility from MDIs
- Impact of capsule selection on formulation stability in dry powder inhalers (DPIs)
- Imaging techniques for dry powder inhaler capsules
- Getting started with CFD
- Gaps in statistical approaches to control of delivered dose uniformity throughout product lifecycle
- Formulation and characterization of nasal sprays
- Examining the influence of carrier lactose on the performance of dry powder inhaler (DPI) formulations: A case study
- Evolution of nasal aerosol products for pain management
- Enhancing drug product portfolios for nasal aerosols and buccal spray delivery systems
- E-cigarettes: Learnings for inhalation scientists
- DPI development: Understanding the technical challenges
- Developing OINDPs using Quality by Design
- Designing a DPI for multiple constituencies
- Design of an inhaler-specific robotic system for laboratory use in early development
- Delivery of inhaled bronchodilators by breath-actuated jet nebulizer: The potential for improved adherence with clinical guidelines
- Considerations in selecting a contract manufacturing organization
- The pressurized metered dose inhaler: Past, present and future perspectives
- The role of intelligent sorbents in respiratory drug delivery devices
- Advantages of capsule-based dry powder inhalers
- Addressing the patient-device use interface: Why patient-friendly features are important
- Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts: A partnership for the assurance of Oral Inhaled Product (OIP) quality
- A “smart” move: The development of electronic devices for nasal aerosols
- Spray pattern: A rapid and sensitive early development tool for respiratory drug products
- What is the future of HFA pMDIs? A patent-based perspective